COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Tokai Pharmaceuticals develops prostate cancer therapies, advancing oral galeterone—an androgen receptor antagonist, CYP17 lyase inhibitor and AR reducer—through ARMOR1 Phase 1 and ARMOR2 Phase 2 trials in CRPC.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors